Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Sept. 17 — Several senators Sept. 17 criticized the head of the FDA's drug center for the lack of guidance on biosimilar labeling and interchangeability.
Janet Woodcock, director of the Food and Drug Administration’s Center for Drug Evaluation and Research, appeared before the Senate Health, Education, Labor and Pensions (HELP) Committee to give a progress report on biosimilars. She said the FDA is still working on draft guidance documents for biosimilar labeling and interchangeability and will get those out “as soon as possible.”
Woodcock said the success of traditional generic drugs didn't happen overnight and although the first biosimilar has been approved, there are still legal and policy challenges ahead.
The Affordable Care Act gave the FDA the authority to approve biosimilars, which are biological products that are approved based on a showing that they are highly similar to already-approved biological products. Yet since the law’s 2010 signing, the agency has approved only one such treatment, Novartis AG’s Zarxio, a biosimilar version of Amgen Inc.’s cancer drug Neupogen.
Zarxio wasn't approved as an interchangeable product, which must meet a tougher standard. Under the ACA's biologics provisions, a biological product that has been approved as an interchangeable may be substituted for the reference, or branded, product without the intervention of the health care provider who prescribed the reference product, the FDA said in March.
“We believe that getting to interchangeability is feasible and we will get there,” Woodcock said. She said the human immune system is capable of detecting a tiny variability in a biosimilar product and the FDA has to make sure the biosimilar doesn't cause additional harm due to unexpected immune responses.
Woodcock also said there are trade-offs involved in various labeling decisions and the FDA needs to have a labeling convention that maintains the trust of physicians.
Sen. Elizabeth Warren (D-Mass.) said “drugmakers need to know the rules of the road,” and she criticized the agency for not releasing the interchangeability and labeling draft guidance documents sooner and for not issuing final versions of other guidances for biosimilars.
“Biosimilars can save an estimated $44 billion over the next 10 years but that will only happen if patients and doctors have confidence in them,” Warren said.
Woodcock said there are 57 biosimilars in development and the agency is meeting with the sponsors of those products and has issued three final guidance documents. In April, the FDA released three final documents intended to make clear the scientific and regulatory considerations for drug companies developing biosimilars.
Sen. Orrin G. Hatch (R-Utah) asked Woodcock about the FDA's proposed naming policy for biosimilars.
In August, the agency released a draft guidance on the nonproprietary naming of biological products, including biosimilars. The draft guidance proposes that reference products and biosimilars have nonproprietary names (also called proper names in the guidance) that share a core drug substance name and, in order to better identify each product, an FDA-designated suffix that is unique for each product. The suffix would be composed of four lowercase letters that won't carry any meaning.
Woodcock said the FDA wants to be able to uniquely identify biosimilars but that the agency doesn't want to hinder switching between products when there are interchangeable biosimilars.
Woodcock also was questioned about a proposed rule from the Centers for Medicare & Medicaid Services on Medicare payments for biosimilars.
The proposed rule (CMS-1631-P), released in July, would assign all biosimilars of a single reference product one Healthcare Common Procedure Coding System (HCPCS) code and would reimburse biosimilars with the same HCPCS code based on the weighted average of their average sales price under Medicare Part B.
Woodcock said the CMS billing codes are often used by the FDA to track drug products. She said that if the proposed rule is made final, the FDA and the CMS plan to develop an approach to use subcodes to distinguish among products if there are multiple biosimilars.
In a press release, the Alliance for Patient Access (AfPA) applauded the committee for holding the hearing.
Biosimilars can offer patients powerful results at potentially reduced prices, the AfPA said. However, questions remain about how to name these medications so that they are distinguishable from the reference biologic for prescribing, dispensing and patient-monitoring purposes. FDA guidance on the critical safety issues of indication extrapolation and medication labeling also remains unresolved, the group said.
The AfPA said it is critical that Congress stay engaged on these issued to ensure that patients have access to approved biosimilars in a manner that ensures transparency and safety.
The AfPA is a national network of physicians dedicated to ensuring patient access to approved therapies and appropriate clinical care, according to its website.
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Brent Bierman at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)